When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. FDA-approved drug for ulcerative colitis also effective for ...

   www.aol.com/fda-approved-drug-ulcerative-colitis...

   Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.

3. Targeted therapy may help treat moderate to severe ulcerative ...

   www.aol.com/targeted-therapy-may-help-treat...

   Challenges of treating ulcerative colitis. People with ulcerative colitis can experience times when inflammation gets worse and when inflammation gets better. Medications can help people with ...

4. Biological therapy for inflammatory bowel disease - Wikipedia

   en.wikipedia.org/wiki/Biological_therapy_for...

   The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]

5. Management of ulcerative colitis - Wikipedia

   en.wikipedia.org/wiki/Management_of_ulcerative...

   Management of ulcerative colitis involves first treating the acute symptoms of the disease, then maintaining remission. Ulcerative colitis is a form of colitis , a disease of the intestine , specifically the large intestine or colon , that includes characteristic ulcers , or open sores, in the colon.

6. Ulcerative colitis - Wikipedia

   en.wikipedia.org/wiki/Ulcerative_colitis

   Standard treatment for ulcerative colitis depends on the extent of involvement and disease severity. The goal is to induce remission initially with medications, followed by the administration of maintenance medications to prevent a relapse. The concept of induction of remission and maintenance of remission is very important.

7. Mirikizumab - Wikipedia

   en.wikipedia.org/wiki/Mirikizumab

   Mirikizumab was developed by Eli Lilly and Company. [11]The approval was based on the LUCENT 1 clinical study which evaluated the safety and efficacy of mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.